Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$322.81
+3.8%
$303.76
$205.87
$333.70
$40.57B0.23855,449 shs1.23 million shs
Galapagos NV stock logo
GLPG
Galapagos
$30.25
-0.1%
$28.33
$22.36
$31.23
N/A0.07255,709 shs259,044 shs
Genmab A/S stock logo
GNMSF
Genmab A/S
$214.95
+1.1%
$208.30
$170.00
$292.80
$14.20B0.9136 shs2 shs
Grifols, S.A. stock logo
GRFS
Grifols
$10.09
+3.3%
$8.62
$6.19
$10.22
$6.72B0.551.05 million shs2.29 million shs
Merck KGaA stock logo
MKGAF
Merck KGaA
$131.88
+4.2%
$132.51
$118.05
$200.56
$17.04B0.961,052 shs10 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+3.76%+0.60%+4.54%+37.62%+29.21%
Galapagos NV stock logo
GLPG
Galapagos
-0.07%+1.34%+5.03%+22.67%+14.71%
Genmab A/S stock logo
GNMSF
Genmab A/S
0.00%-0.02%-3.40%+7.15%-17.38%
Grifols, S.A. stock logo
GRFS
Grifols
+3.28%+7.45%+11.00%+42.51%+23.80%
Merck KGaA stock logo
MKGAF
Merck KGaA
+4.25%-1.65%-1.22%+3.63%-19.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
4.0102 of 5 stars
2.44.00.04.32.62.50.6
Galapagos NV stock logo
GLPG
Galapagos
0.4131 of 5 stars
0.84.00.00.01.60.00.6
Genmab A/S stock logo
GNMSF
Genmab A/S
0.2218 of 5 stars
0.01.00.00.01.60.01.3
Grifols, S.A. stock logo
GRFS
Grifols
3.5299 of 5 stars
1.55.00.00.02.50.05.0
Merck KGaA stock logo
MKGAF
Merck KGaA
1.9524 of 5 stars
0.03.00.00.02.20.03.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.80
Moderate Buy$346.137.22% Upside
Galapagos NV stock logo
GLPG
Galapagos
1.50
Reduce$25.33-16.25% Downside
Genmab A/S stock logo
GNMSF
Genmab A/S
0.00
N/AN/AN/A
Grifols, S.A. stock logo
GRFS
Grifols
3.00
Buy$10.302.08% Upside
Merck KGaA stock logo
MKGAF
Merck KGaA
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest GNMSF, ALNY, MKGAF, GLPG, and GRFS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$338.00 ➝ $348.00
7/11/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$364.00 ➝ $404.00
7/11/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$336.00 ➝ $359.00
7/7/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$328.00 ➝ $384.00
6/30/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$287.00 ➝ $333.00
6/26/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$320.00 ➝ $377.00
6/24/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$300.00 ➝ $360.00
6/17/2025
Grifols, S.A. stock logo
GRFS
Grifols
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.60 ➝ $10.30
6/12/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$330.00 ➝ $338.00
5/2/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$331.00 ➝ $349.00
5/2/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$300.00 ➝ $325.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$2.25B18.72N/AN/A$0.52 per share620.79
Galapagos NV stock logo
GLPG
Galapagos
$298.31MN/A$0.73 per share41.69$47.57 per shareN/A
Genmab A/S stock logo
GNMSF
Genmab A/S
$3.12B4.55$15.19 per share14.15$80.53 per share2.67
Grifols, S.A. stock logo
GRFS
Grifols
$7.81B0.89$0.97 per share10.44$13.55 per share0.74
Merck KGaA stock logo
MKGAF
Merck KGaA
$22.72B0.75$39.72 per share3.32$212.00 per share0.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$278.16M-$2.09N/A362.71N/A-11.49%-510.31%-6.48%8/7/2025 (Estimated)
Galapagos NV stock logo
GLPG
Galapagos
$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.14B$17.6312.19N/A35.11%19.23%15.44%8/7/2025 (Estimated)
Grifols, S.A. stock logo
GRFS
Grifols
$169.80M$1.178.629.610.35N/AN/AN/A7/29/2025 (Estimated)
Merck KGaA stock logo
MKGAF
Merck KGaA
$3.06B$6.8120.1312.50N/A12.60%10.17%5.74%8/7/2025 (Estimated)

Latest GNMSF, ALNY, MKGAF, GLPG, and GRFS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$0.0538N/AN/AN/A$633.54 millionN/A
7/29/2025Q2 2025
Grifols, S.A. stock logo
GRFS
Grifols
$0.2221N/AN/AN/A$1.92 billionN/A
7/23/2025Q2 2025
Galapagos NV stock logo
GLPG
Galapagos
-$0.34N/AN/AN/A$80.13 millionN/A
5/8/2025Q1 2025
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.88$3.05+$1.17$3.05$761.09 million$765.14 million
5/1/2025Q1 2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$0.37-$0.44-$0.07-$0.44$584.32 million$594.19 million
4/23/2025Q1 2025
Galapagos NV stock logo
GLPG
Galapagos
-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Galapagos NV stock logo
GLPG
Galapagos
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GNMSF
Genmab A/S
N/AN/AN/AN/AN/A
Grifols, S.A. stock logo
GRFS
Grifols
N/AN/AN/AN/AN/A
Merck KGaA stock logo
MKGAF
Merck KGaA
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8.88
3.04
2.98
Galapagos NV stock logo
GLPG
Galapagos
N/A
7.95
7.86
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
5.34
5.32
Grifols, S.A. stock logo
GRFS
Grifols
1.13
2.60
0.97
Merck KGaA stock logo
MKGAF
Merck KGaA
0.27
1.31
0.84

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Galapagos NV stock logo
GLPG
Galapagos
32.46%
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
Grifols, S.A. stock logo
GRFS
Grifols
N/A
Merck KGaA stock logo
MKGAF
Merck KGaA
0.10%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
1.50%
Galapagos NV stock logo
GLPG
Galapagos
2.91%
Genmab A/S stock logo
GNMSF
Genmab A/S
1.54%
Grifols, S.A. stock logo
GRFS
Grifols
0.19%
Merck KGaA stock logo
MKGAF
Merck KGaA
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,230130.39 million128.43 millionOptionable
Galapagos NV stock logo
GLPG
Galapagos
1,310N/AN/AOptionable
Genmab A/S stock logo
GNMSF
Genmab A/S
2,68266.07 million65.06 millionNot Optionable
Grifols, S.A. stock logo
GRFS
Grifols
23,822687.55 million686.25 millionOptionable
Merck KGaA stock logo
MKGAF
Merck KGaA
62,908129.24 millionN/ANot Optionable

Recent News About These Companies

Merck KGaA (OTCMKTS:MKGAF) Shares Gap Up - Here's Why
Merck KGaA (OTCMKTS:MKGAF) Shares Gap Down - What's Next?
Merck KGaA celebrates 350 years of innovation
Merck KGaA (MKGAF) Q1 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$322.81 +11.69 (+3.76%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$322.95 +0.14 (+0.04%)
As of 07/16/2025 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Galapagos stock logo

Galapagos NASDAQ:GLPG

$30.24 -0.03 (-0.10%)
As of 07/16/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Genmab A/S stock logo

Genmab A/S OTCMKTS:GNMSF

$214.95 +2.40 (+1.13%)
As of 07/11/2025

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Grifols stock logo

Grifols NASDAQ:GRFS

$10.09 +0.32 (+3.28%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$9.70 -0.39 (-3.86%)
As of 07/16/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Merck KGaA stock logo

Merck KGaA OTCMKTS:MKGAF

$131.88 +5.37 (+4.25%)
As of 07/16/2025 11:43 AM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.